🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re #hiring a Director/ Sr. Director of Clinical Sciences to drive strategy in our #oncology programs and other therapeutic areas. This position will report to our CMO, shaping and overseeing trials and contributing to regulatory filings. Learn more: bit.ly/3Ek0rlL

Happy Employee Appreciation Day to the amazing team at Solu Therapeutics! Thank you for your dedication and hard work in advancing our mission. #EmployeeAppreciation #TeamSolu

This #InternationalWomensDay, we celebrate the women of Solu Therapeutics and across #biotech who are shaping the #FutureOfMedicine. Their expertise, innovation, and dedication are driving scientific progress, advancing new treatments, and redefining what’s possible in medicine.

Our TicTAC™ platform links small molecules to Fc-modified antibodies, which may offer a new approach to targeted therapies. Learn more about TicTAC and our ongoing work: solutheraeutics.com/#platform

Continuing our celebration of #WomensHistoryMonth, we’re proud to spotlight Michelle Baptista, Senior Research Associate at Solu. Michelle plays a pivotal role in advancing our #oncology and #immunology research, driving innovation to improve patient outcomes.

Chronic myelomonocytic leukemia (#CMML) remains a disease with limited treatment options, despite advances in related hematological malignancies. An ASH article highlights insights on advancing drug development for these underserved patients: ashpublications.org/blood/article/…

This #WorldHealthDay, we join World Health Organization (WHO) in advocating for #HealthForAll. We’re advancing breakthrough therapies in #oncology and #immunology through our CyTAC™ and TicTAC™ platforms to address critical unmet needs. Learn more: who.int/campaigns/worl…

We’re pleased to announce the closing of our $41M Series A financing & the dosing of the first patient in our Phase 1 #CMML study. This funding supports the continued advancement of our CyTAC™ platform and pipeline, including new efforts in #immunology. bit.ly/42owBok

We’re grateful for the support of The Leukemia & Lymphoma Society through their Therapy Acceleration Program (TAP). This new partnership will help drive our efforts in hematological malignancies, particularly #CMML, as we work toward innovative solutions for patients. Read more: lls.org/research/solu-…

Next week, we’re heading to Chicago for AACR meeting to share new data on our CCR2-directed CyTAC™ approach for targeting immunosuppressive myeloid cells in the tumor microenvironment. Our team will present on April 29 at 9am. Read the abstract: abstractsonline.com/pp8/#!/20273/p… #AACR25

Earlier this month, we dosed the first patient in our #CMML study and took a moment to celebrate with the team. Grateful for the hard work that brought us here—and focused on what comes next. #ICYMI, here’s the press release: bit.ly/42owBok

Behind every program milestone is a team of dedicated admin professionals who keep our operations running smoothly. This #AdministrativeProfessionalsDay, we’re highlighting our new Sr. Executive Assistant to CEO & Office Manager, Sara. Thank you for all of your work!

That’s a wrap on #AACR25! Plenty of great discussions, meaningful connections, and exciting science. Thanks to everyone who joined our presentation on CCR2-directed depletion of mMDSCs using our CyTAC™ platform—we appreciate the engagement from the #oncology community. #AACR25

Thank you to Hannah Green and Boston Business Journal for highlighting of our $41M Series A & the dosing of the first patient in our #CMML study. Check out the full article: bit.ly/44tH4S4

#ICYMI: We’ve initiated our Phase 1 trial for our #CMML program—an important step in addressing this aggressive blood cancer. This milestone follows our preclinical data at December’s #ASH24 & highlights the progress of our CyTAC™ platform. More: bit.ly/42owBok

Last week, Solu turned 2! We’ve gone from concept to clinic—launching our Phase 1 study, advancing our CyTAC™ & TicTAC™ platforms and programs, and expanding our pipeline in oncology, immunology & chronic pain. Thanks to our team, partners & supporters. solutherapeutics.com

May is #NationalCancerResearchMonth, a time to honor the researchers, clinicians, and advocates driving progress for patients. We’re inspired by their resilience as we work to develop new therapies for blood cancers like #CMML. Learn more: solutherapeutics.com/#oncology

We’re headed to Chicago next weekend for #ASCO25. Our team will be on-site connecting with #oncology leaders to discuss our work in #CMML. Learn more and register here: asco.org/annual-meeting

For #NationalCancerResearchMonth, we're highlighting #CMML—a complex blood cancer that affects the bone marrow and blood cells. At Solu, we're advancing research in CMML alongside groups like The Leukemia & Lymphoma Society to improve options for patients. Learn more: lls.org

#ASCO25 in Chicago is here! Our CEO Phil Vickers, CMO Sergio Santillana, CSO Brandon Turunen, & VP of Clinical Operations Marissa Timothy are on-site, excited to connect with #oncology innovators and advance care for patients with hematologic malignancies.